About
Titles
Hospital Resident
Appointments
Departments & Organizations
Education & Training
- MD
- Yale School of Medicine (2022)
- BS
- Yale College, Molecular, Cellular, and Developmental Biology (2017)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Gathe Kiwan's published research.
Alan Dardik, MD/PhD, FACS, DFSVS, FAHA
Carlos Mena-Hurtado, MD, FACC, FSCAI, FAHA
Hamid Mojibian, MD
Luis Gonzalez
Cassius Iyad Ochoa Chaar, MD, MPH, MS, RPVI
Publications
2022
The Impact of Clinical Follow-Up After Revascularization on the Outcomes of Patients with Chronic Limb Threatening Ischemia
Kiwan G, Mohamedali A, Kim T, Zhuo H, Zhang Y, Mena-Hurtado C, Mojibian H, Cardella J, Ochoa Chaar CI. The Impact of Clinical Follow-Up After Revascularization on the Outcomes of Patients with Chronic Limb Threatening Ischemia. Annals Of Vascular Surgery 2022, 86: 286-294. PMID: 35803459, DOI: 10.1016/j.avsg.2022.05.043.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLower extremity revascularizationReintervention rateCompliant patientsNoncompliant patientsLimb amputationSingle-center retrospective chart reviewChronic limb threatening ischemiaOverall reintervention rateOutcomes of patientsLimb threatening ischemiaMajor amputation ratePeripheral arterial diseaseRetrospective chart reviewLong-term outcomesMajor limb amputationImpact of ClinicalSignificant differencesMajor amputationAmputation ratePerioperative outcomesBaseline characteristicsChart reviewExtremity revascularizationIschemia patientsMore reinterventions
2021
PD-L1 (Programmed Death Ligand 1) Regulates T-Cell Differentiation to Control Adaptive Venous Remodeling
Matsubara Y, Gonzalez L, Kiwan G, Liu J, Langford J, Gao M, Gao X, Taniguchi R, Yatsula B, Furuyama T, Matsumoto T, Komori K, Mori M, Dardik A. PD-L1 (Programmed Death Ligand 1) Regulates T-Cell Differentiation to Control Adaptive Venous Remodeling. Arteriosclerosis Thrombosis And Vascular Biology 2021, 41: 2909-2922. PMID: 34670406, PMCID: PMC8664128, DOI: 10.1161/atvbaha.121.316380.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPD-L1AVF maturationPD-L1 activityVenous remodelingT cellsL1 antibodyArteriovenous fistulaNude miceMouse aortocaval fistula modelEnd-stage renal diseaseT helper type 2 cellsT helper type 1 (Th1) cellsPrimary success rateSmooth muscle cell proliferationRegulatory T cellsT cell activityT-cell transferAortocaval fistula modelPreferred vascular accessVascular wall thickeningM1-type macrophagesM2-type macrophagesPotential therapeutic targetMuscle cell proliferationType 1 cellsInhibition of T-Cells by Cyclosporine A Reduces Macrophage Accumulation to Regulate Venous Adaptive Remodeling and Increase Arteriovenous Fistula Maturation
Matsubara Y, Kiwan G, Liu J, Gonzalez L, Langford J, Gao M, Gao X, Taniguchi R, Yatsula B, Furuyama T, Matsumoto T, Komori K, Dardik A. Inhibition of T-Cells by Cyclosporine A Reduces Macrophage Accumulation to Regulate Venous Adaptive Remodeling and Increase Arteriovenous Fistula Maturation. Arteriosclerosis Thrombosis And Vascular Biology 2021, 41: e160-e174. PMID: 33472405, PMCID: PMC7904667, DOI: 10.1161/atvbaha.120.315875.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsVascular wall thickeningT helper type 1 (Th1) cellsSuccessful AVF maturationAVF maturationRegulatory T cellsMacrophage accumulationT cellsType 1 cellsArteriovenous fistulaVenous remodelingWall thickeningMouse aortocaval fistula modelT helper type 2T helper type 2 cellsAdaptive remodelingM2 macrophage accumulationPrimary success rateAortocaval fistula modelArteriovenous fistula maturationPreferred vascular accessAnti-inflammatory macrophagesT cell functionWild-type miceEffect of CsAType 2 cells
2020
Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease
Kim TI, Kiwan G, Mohamedali A, Zhang Y, Mena-Hurtado C, Mojibian H, Guzman RJ, Ochoa Chaar CI. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease. Journal Of Vascular Surgery 2020, 73: 911-917. PMID: 33038480, DOI: 10.1016/j.jvs.2020.08.146.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAgedAged, 80 and overAmputation, SurgicalCardiovascular AgentsCoated Materials, BiocompatibleDrug-Eluting StentsEndovascular ProceduresFemaleHumansLimb SalvageMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProsthesis DesignRetreatmentRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeVascular PatencyConceptsPaclitaxel-coated devicesPeripheral artery diseaseCause of mortalityPCD useRisk of mortalityCumulative doseFemoropopliteal peripheral artery diseaseKaplan-Meier survival curvesLong-term mortalityPeripheral arterial diseaseCox regression analysisDrug-coated balloonsOutcome of treatmentDrug-eluting stentsMajor amputationPrimary patencyReintervention rateArtery diseaseArterial diseaseRandomized trialsOpen surgeryPresent studySingle institutionEndovascular interventionPatientsDistinct subsets of T cells and macrophages impact venous remodeling during arteriovenous fistula maturation
Matsubara Y, Kiwan G, Fereydooni A, Langford J, Dardik A. Distinct subsets of T cells and macrophages impact venous remodeling during arteriovenous fistula maturation. JVS Vascular Science 2020, 1: 207-218. PMID: 33748787, PMCID: PMC7971420, DOI: 10.1016/j.jvssci.2020.07.005.Peer-Reviewed Original ResearchCitationsConceptsArteriovenous fistulaT cellsVascular remodelingAVF maturationFistula maturationVascular accessEnd-stage renal failureImmunosuppressive drug developmentInflammatory cell subsetsPatent vascular accessArterial blood pressureArteriovenous fistula maturationPreferred vascular accessRegulation of inflammationPrimary patencyTotal immunosuppressionAdaptive vascular remodelingRenal transplantationRenal failureBlood pressureCell subsetsVenous remodelingLonger patencyM2 macrophagesNeointimal hyperplasia
Get In Touch
Contacts
Email